Genetron Holdings is a holding company. Through its subsidiaries, Co. is an oncology platform company in the People's Republic of China (China) that focuses on cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. Co. has developed a product and service portfolio that cover the cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. Co. provides diagnosis and monitoring services and products through laboratory developed tests services and in vitro diagnostics products. Co.'s diagnostic products and services cover various cancer types in China. The GTH average annual return since 2020 is shown above.
The Average Annual Return on the GTH average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GTH average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GTH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|